February 8, 2025 Week in Review: Trade Wars, Earnings, and Labor Data
February 4, 2025 AI Ventures Soar as Trade Tensions Heat Up – Key Weekly Highlights
Tesla's Shanghai Megapack Factory: A Catalyst for Future Growth
Nvidia: Seizing Long-Term Growth Amid Cost Challenges and AI Momentum
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
January 21, 2025 Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025
January 1, 2025 Advanced Charting Tools For Traders
December 21, 2024 Why Is Trading Important?
Teva (TEVA) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: February 16, 2025 (09:58)
Sector: HealthcareThe share price of Teva Pharmaceutical Industries Lim. (TEVA) (TEVA) now
News Impact Analyzer
Full report
This Week
|
Bullish | Impact: 5 | News: 2 (1/1/0) |
Previous Week
|
Bearish | Impact: 5 | News: 3 |
Two Weeks Ago
|
Bearish | Impact: 1.67 | News: 4 (1/1/2) |
Three Weeks Ago
|
Bearish | Impact: 5 | News: 2 |
Analysts predictions
Full report
This Week
|
Neutral | Opinions: 1 |
Previous Week
|
Neutral | Opinions: Na |
Two Weeks Ago
|
Neutral | Opinions: 1 |
Three Weeks Ago
|
Neutral | Opinions: Na |
Analyzing the Most Important TEVA news

Axsome and Teva Reach Settlement Over Antidepressant Patent Clash


Teva Completes Phase 3 Trial for Long-Acting Schizophrenia Drug


Teva Pharmaceuticals Announces Potential for Multi-Security Capital Raise

Historical and forecast chart of Teva stock
The chart below shows the historical price of Teva stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Teva stock price can be found in the table below.
Long-term forecasts by years.
Teva Pharmaceutical Industries Lim. (TEVA) Analysts predictions review

Teva Pharmaceuticals faces near-term challenges from revised guidance, generic drug pricing pressures, legal liabilities, and macroeconomic risks like inflation and supply chain disruptions. However, its strategic shift towards high-margin specialty drugs, pipeline strength in biosimilars and innovative products like Duvakitug, and cost optimization initiatives signal potential for long-term recovery. Execution risks, competition, and regulatory dependencies remain key concerns. Investors should adopt a cautious stance given the balance of opportunities and risks.

Teva Pharmaceutical: 2025 Guidance Unveils Short-Term Risks, Long-Term Potential

Teva Pharmaceutical's revised 2025 guidance has been a key trigger for the stock's recent decline. A downward adjustment in revenue and profitability expectations signals near-term challenges in sustaining growth, reflecting ongoing pressure from generic drug pricing and legislative risks. These factors have notably tempered investor sentiment, amplifying volatility in the stock.
Potential Catalysts for Value Recovery Despite Challenges
Despite the lowered guidance, the company's focus on cost optimization and its ongoing pivot towards higher-margin specialty drugs could provide a medium to long-term growth runway. This strategic shift aligns with an evolving market environment and could help Teva mitigate margin compression in the commoditized generics segment.
Additionally, the pipeline of biosimilars and novel therapeutics remains an underappreciated asset in Teva's portfolio. Successful commercialization of these products could unlock significant value, compensating for revenue pressure in traditional segments and sparking a stock recovery over time.

Evaluating TEVA Pharmaceuticals: A Strategic Outlook Amid Immunology Market Growth

TEVA Pharmaceuticals stands at a critical juncture within the immunology sector, benefiting from its diversified portfolio and a solid pipeline of drug development. Its position as a major player in the generic drugs market continues to provide the company with a cash flow safety net, enabling long-term investments in innovative treatments. However, intense competition in both generics and specialty drugs remains a notable pressure point for margins.
Growth Drivers and Challenges for TEVA
TEVA's recent focus on expanding its immunology offerings reflects a strategic pivot towards high-margin specialty drugs to counteract ongoing pricing struggles in the generics segment. This shift is likely to bolster revenue growth in the medium to long term if clinical trials and regulatory approvals proceed as planned. Additionally, the company's cost optimization measures, including facility consolidations and operating expense reductions, signal improved efficiency and profitability potential, which investors will closely monitor for tangible results in quarterly earnings.
On the downside, ongoing legal liabilities from opioid-related settlements present a recurring headwind for TEVA, adding uncertainty to future cash flow allocations. Moreover, foreign exchange volatility, given its significant international footprint, could further pressure earnings in the near term.
The author underscores that while TEVA exhibits significant long-term potential tied to its R&D efforts and market pivots, near-term risks warrant a cautious approach. Investors seeking exposure should weigh these opportunities against the risks of delayed regulatory approvals and macroeconomic challenges.

Teva Pharmaceuticals: Evaluating Duvakitug's Role in Long-Term Growth

Teva Pharmaceuticals' strategic focus on Duvakitug, a novel pharmaceutical product, highlights the company's efforts to revitalize its growth trajectory amidst a challenging competitive landscape. The drug is positioned as a potential breakthrough in its therapeutic category, potentially driving meaningful revenue growth if it gains strong market adoption and regulatory support. The author emphasizes the significance of this pipeline asset, underscoring its role in boosting confidence in Teva's innovation capabilities and long-term value.
Macroeconomic Environment and Operational Challenges
Broader macroeconomic conditions, including inflationary pressures and global supply chain disruptions, remain critical challenges for Teva. These factors could compress margins and slow operational recovery, especially as the company continues its debt-reduction efforts. The author also notes increased competition in the generics market, which may dampen price growth and offset revenue gains from innovative products like Duvakitug.
Cost management initiatives and restructuring measures are additional levers influencing Teva’s financial health. While these actions may enhance operational efficiency, they are not without execution risks that could delay the realization of cost savings. Furthermore, litigation risks stemming from opioid-related settlements could weigh on investor sentiment and potentially impact near-term stock performance.
Teva's operational fundamentals have shown significant improvement, particularly through its consistent focus on debt reduction and cost efficiencies. These actions signal strong financial discipline that enhances long-term sustainability, though they may have minimal immediate impact on driving the stock price higher in the near term.
Valuation and Growth Outlook
The author's analysis suggests that Teva's current valuation aligns with its improving fundamentals, reducing the likelihood of it being an undervalued opportunity. This equilibrium limits substantial upside potential unless new growth catalysts emerge or sector-wide sentiment improves.
Additionally, short-term headwinds, such as ongoing legal challenges and competition in generic drugs, remain key risks restraining price momentum. These elements weigh on investor confidence and have the potential to maintain pressure on the stock's near-term performance.
Teva Pharmaceuticals is capitalizing on its position as a leading generic drug manufacturer, which continues to drive stable revenue, particularly amidst rising demand for cost-effective healthcare solutions. The company’s dominance in generics insulates it against major competitive pressures, enhancing its allure as a long-term investment.
Leveraging Financial Discipline and Growth Prospects
Teva’s proactive debt reduction strategy has significantly strengthened its balance sheet, lowering financial risk and enhancing its capacity to reinvest in core operations. The removal of onerous financial obligations improves investor sentiment and positions the company for better forward-looking profitability.
Growth indicators, including new product launches and strategic market expansions, highlight management’s focus on innovation and operational efficiency. These developments provide tailwinds for revenue acceleration and improved market positioning in the near to medium term.
Finally, macroeconomic factors such as inflationary pressures and global healthcare trends are likely to favor Teva’s cost-effective drug offerings. As governments and insurers push for reduced healthcare expenditures, Teva is well-placed to benefit from elevated demand in key markets.
Comprehensive Analysis of Teva (TEVA) Stock Market Performance
Our multifaceted analysis of Teva 's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Teva stock?
- When should I record a loss on Teva stock?
- What are analysts' forecasts for Teva stock?
- What is the future of Teva stock?
We forecast Teva stock performance using neural networks based on historical data on Teva stocks.
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generics, specialty drugs and biopharmaceutical products in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic agents in a variety of dosage forms, including tablets, capsules, injections, inhalers, liquids, ointments and creams. It also develops, manufactures and markets active pharmaceutical ingredients. In addition, the company provides specialized medicines for use in the central nervous system and respiratory indications. In addition, its products in the central nervous system and pain areas include Copaxone for the treatment of relapsing forms of MS; ADZHOVIY for the prophylactic treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. In addition, the company’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair / Cinqaero and AirDuo RespiClick / ArmonAir RespiClick / AirDuo Digihaler for asthma and chronic obstructive pulmonary disease, as well as Bendeka products , Trisenox, Lonquex and Tevagrastim / Ratiograstim in the cancer market. She has cooperation agreements with Otsuka Pharmaceutical Co. LTD. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petah Tikva, Israel.
Teva Pharmaceutical Industries Lim. (TEVA) News influencing stock rates

As of now, Panda has combed through 11 news items directly related to TEVA from the last 30 days. Out of these, 2 clearly showcase a bullish trend, while 5 display bearish tendencies, and 4 events are neutral.
The strength of the bearish trend is dominating bullish sentiments by 2.06 times, indicating that the current news landscape is negatively impacting the company's stock prices in the foreseeable future.
The news analyzed fell within the period from Jan 17, 2025, to Feb 10, 2025.
Teva Pharmaceutical Rebounds After 20% Plunge in Six Sessions


Tariff Concerns Loom Over Pharma Distributors and Generic Drugmakers


Stock Market Spotlight: Key Movers on Earnings Day


Teva Surpasses Q4 Expectations: Sets Bold 2025 Outlook


Teva Stumbles as 2025 Earnings Fall Short


Teva Faces Uphill Struggle with Q4 Earnings Decline


FDA Flags Severe Allergy Risk in Teva's Copaxone


Teva Challenges Medicare Drug Pricing in Court


Teva Expands European Footprint with Eylea Biosimilar Deal


Teva Teams Up with Samsung Bioepis for U.S. Biosimilar Launch of EPYSQLI


Teva daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Feb 18 | 17.58 | 16.97 | 17.81 | 4.97 |
Feb 19 | 17.39 | 16.64 | 18.04 | 8.40 |
Feb 20 | 17.78 | 17.56 | 18.41 | 4.86 |
Feb 21 | 16.82 | 16.23 | 17.62 | 8.58 |
Feb 22 | 17.75 | 17.00 | 18.40 | 8.27 |
Feb 23 | 17.66 | 17.03 | 18.10 | 6.28 |
Feb 24 | 17.75 | 17.37 | 18.20 | 4.78 |
Feb 25 | 17.69 | 17.09 | 18.49 | 8.13 |
Feb 26 | 17.91 | 17.40 | 18.59 | 6.86 |
Feb 27 | 17.47 | 17.24 | 18.01 | 4.44 |
Feb 28 | 16.46 | 16.02 | 16.89 | 5.43 |
Mar 01 | 17.09 | 16.80 | 17.90 | 6.53 |
Mar 02 | 17.98 | 17.17 | 18.27 | 6.41 |
Mar 03 | 19.06 | 18.46 | 19.63 | 6.32 |
Mar 04 | 18.74 | 18.02 | 19.27 | 6.93 |
Mar 05 | 18.30 | 17.81 | 18.91 | 6.23 |
Mar 06 | 19.19 | 18.71 | 19.73 | 5.48 |
Mar 07 | 19.43 | 19.12 | 19.76 | 3.35 |
Mar 08 | 18.92 | 18.47 | 19.51 | 5.59 |
Mar 09 | 18.87 | 18.39 | 19.40 | 5.54 |
Mar 10 | 18.89 | 18.58 | 19.25 | 3.60 |
Mar 11 | 18.58 | 18.20 | 19.09 | 4.90 |
Mar 12 | 19.38 | 18.68 | 19.81 | 6.04 |
Mar 13 | 19.67 | 19.16 | 20.18 | 5.30 |
Mar 14 | 20.19 | 19.55 | 20.65 | 5.64 |
Mar 15 | 21.22 | 20.34 | 22.15 | 8.89 |
Mar 16 | 20.52 | 19.55 | 20.93 | 7.05 |
Mar 17 | 19.31 | 18.57 | 19.95 | 7.42 |
Mar 18 | 19.27 | 19.04 | 19.61 | 3.04 |
Mar 19 | 19.51 | 19.22 | 20.22 | 5.24 |
Teva Daily Price Targets
Teva Stock Forecast 02-18-2025.
Forecast target price for 02-18-2025: $17.58.
Positive dynamics for Teva shares will prevail with possible volatility of 4.737%.
Pessimistic target level: 16.97
Optimistic target level: 17.81
Teva Stock Forecast 02-19-2025.
Forecast target price for 02-19-2025: $17.39.
Negative dynamics for Teva shares will prevail with possible volatility of 7.751%.
Pessimistic target level: 16.64
Optimistic target level: 18.04
Teva Stock Forecast 02-20-2025.
Forecast target price for 02-20-2025: $17.78.
Positive dynamics for Teva shares will prevail with possible volatility of 4.633%.
Pessimistic target level: 17.56
Optimistic target level: 18.41
Teva Stock Forecast 02-21-2025.
Forecast target price for 02-21-2025: $16.82.
Negative dynamics for Teva shares will prevail with possible volatility of 7.901%.
Pessimistic target level: 16.23
Optimistic target level: 17.62
Teva Stock Forecast 02-22-2025.
Forecast target price for 02-22-2025: $17.75.
Positive dynamics for Teva shares will prevail with possible volatility of 7.641%.
Pessimistic target level: 17.00
Optimistic target level: 18.40
Teva Stock Forecast 02-23-2025.
Forecast target price for 02-23-2025: $17.66.
Negative dynamics for Teva shares will prevail with possible volatility of 5.911%.
Pessimistic target level: 17.03
Optimistic target level: 18.10
TEVA (TEVA) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Mar. | 15.86 | 15.00 | 16.39 | 8.51 |
Apr. | 16.14 | 15.29 | 18.05 | 15.31 |
May. | 15.78 | 14.72 | 17.34 | 15.14 |
Jun. | 13.30 | 12.62 | 13.77 | 8.35 |
Jul. | 11.24 | 10.70 | 12.46 | 14.14 |
Aug. | 11.22 | 10.25 | 12.23 | 16.15 |
Sep. | 10.82 | 9.87 | 12.12 | 18.57 |
Oct. | 11.40 | 10.28 | 12.02 | 14.42 |
Nov. | 11.85 | 11.42 | 12.59 | 9.34 |
Dec. | 10.77 | 9.77 | 11.74 | 16.74 |
Teva forecast for this year
Teva Stock Prediction for Mar 2025
An downtrend is forecast for this month with an optimal target price of $15.8584. Pessimistic: $15.00. Optimistic: $16.39
Teva Stock Prediction for Apr 2025
An uptrend is forecast for this month with an optimal target price of $16.1375. Pessimistic: $15.29. Optimistic: $18.05
Teva Stock Prediction for May 2025
An downtrend is forecast for this month with an optimal target price of $15.776. Pessimistic: $14.72. Optimistic: $17.34
Teva Stock Prediction for Jun 2025
An downtrend is forecast for this month with an optimal target price of $13.3023. Pessimistic: $12.62. Optimistic: $13.77
Teva Stock Prediction for Jul 2025
An downtrend is forecast for this month with an optimal target price of $11.2378. Pessimistic: $10.70. Optimistic: $12.46
Teva Stock Prediction for Aug 2025
An downtrend is forecast for this month with an optimal target price of $11.2198. Pessimistic: $10.25. Optimistic: $12.23
Teva Stock Prediction for Sep 2025
An downtrend is forecast for this month with an optimal target price of $10.8249. Pessimistic: $9.87. Optimistic: $12.12
Teva Stock Prediction for Oct 2025
An uptrend is forecast for this month with an optimal target price of $11.3964. Pessimistic: $10.28. Optimistic: $12.02
Teva Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $11.8523. Pessimistic: $11.42. Optimistic: $12.59
Teva Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $10.7714. Pessimistic: $9.77. Optimistic: $11.74
Teva (TEVA) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 10.55 | 9.77 | 10.92 | 10.51 |
Feb | 10.02 | 8.87 | 11.31 | 21.56 |
Mar | 9.75 | 9.27 | 10.42 | 11.08 |
Apr | 11.28 | 10.11 | 12.15 | 16.79 |
May | 11.61 | 10.57 | 12.63 | 16.32 |
Jun | 11.55 | 11.11 | 12.71 | 12.65 |
Jul | 12.31 | 11.42 | 13.80 | 17.26 |
Aug | 13.15 | 11.77 | 13.64 | 13.73 |
Sep | 13.43 | 12.46 | 14.18 | 12.12 |
Oct | 13.45 | 12.95 | 14.33 | 9.61 |
Nov | 12.14 | 11.61 | 12.93 | 10.21 |
Dec | 11.65 | 10.96 | 12.15 | 9.82 |
Teva (TEVA) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 11.52 | 10.27 | 12.87 | 20.20 |
Feb | 10.69 | 9.84 | 12.04 | 18.32 |
Mar | 12.26 | 11.42 | 13.34 | 14.41 |
Apr | 13.05 | 11.42 | 13.80 | 17.25 |
May | 12.95 | 11.29 | 13.46 | 16.15 |
Jun | 13.69 | 13.10 | 14.41 | 9.12 |
Jul | 11.87 | 10.54 | 13.28 | 20.60 |
Aug | 12.23 | 11.14 | 13.39 | 16.81 |
Sep | 10.63 | 10.29 | 11.94 | 13.82 |
Oct | 10.17 | 9.45 | 11.02 | 14.18 |
Nov | 10.80 | 10.29 | 11.98 | 14.14 |
Dec | 10.56 | 9.60 | 10.92 | 12.07 |
Teva information and performance
5 BAZEL ST, P O B 3190, PETACH TIKVA, IL
Market capitalization of the Teva Pharmaceutical Industries Lim. (TEVA) is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TEVA shares in the company outstanding by the market price of one share.
EBITDA of Teva is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Teva (TEVA) stock dividend
Teva last paid dividends on 11/27/2017. The next scheduled payment will be on 12/12/2017. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Teva Stock)
Should I Buy Teva Shares in 2025 year?
Does Teva pay dividends?
Which economic sector do Teva 's shares belong to?
Which other securities belong to the same sector as Teva 's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.